Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2005
03/23/2005CN1599613A Combinations for the treatment of immunoinflammatory disorders
03/23/2005CN1599612A Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
03/23/2005CN1599608A Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/23/2005CN1599607A Carbinols for the treatment of neuropathic dysfunction
03/23/2005CN1599604A Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
03/23/2005CN1599603A Method of stabilizing reduced coenzyme Q10
03/23/2005CN1599602A Peroxisome proliferator activated receptor ligands and process for producing the same
03/23/2005CN1597952A Nerve growth factor cDNA, clone and expresion of Chinese cobra
03/23/2005CN1597697A Human parathyrin 1.34 peptide related peptide-Pro-Pro-[Arg11 hPTH (1.34)-Pro-Pro
03/23/2005CN1597689A Ledebouriella root glycoside and its preparation and application
03/23/2005CN1597677A Compounds and methods for modulation of estrogen receptors
03/23/2005CN1597667A Quinazoline derivatives as angiogenesis inhibitors
03/23/2005CN1596928A Medicine for treating diabetes
03/23/2005CN1596913A Liver-nourishing kidney protecting fat lowering tea
03/23/2005CN1596911A Production method of enzymolysis forest frog oil and softcapsule
03/23/2005CN1596901A Ledebouriella root extract preparation used for treating climacteric syndrome and preparation method
03/23/2005CN1596887A Application use of dihydromyricetrin
03/23/2005CN1596884A Composition containing high content conjugated linoleic acid and its preparation method
03/23/2005CN1596882A Vitamin K1 emulsion and its freeze-dried emulsion and preparation method
03/23/2005CN1193760C Licorzinc solution composition, preparation process tereof and licorxinc preparation
03/23/2005CN1193752C Tetrahydrolipstatin-containing compositions
03/23/2005CN1193743C Multilayer pharmaceutical product for release in the colon
03/22/2005US6870070 Hydrogenation, resoulution, alkylation, bromination, andcarboxamidation
03/22/2005US6869975 Linked biaryl compounds
03/22/2005US6869966 N-substituted-2-oxodihydropyridine derivatives
03/22/2005US6869962 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
03/22/2005US6869960 Substituted with a quinolin-3-ylmethyl- group, e.g., 2,3-dihydro-1'-((2-oxo-1,2,3,4-tetrahydro-3-quinolinyl)-methyl)spiro(1H -indene-1,4'-piperidine)
03/22/2005US6869959 Heterocyclic carboxylic acid derivatives
03/22/2005US6869952 Such as 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo(2,1-f)(1,2,4)triazin-6-ol; for treament of cancer
03/22/2005US6869950 Such as 1-(2-chloro-4-(n-octyloxy)benzyl)-2-methyl-6-(1-pentane -sulfonylcarbamoyl)benzimidazole
03/22/2005US6869947 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
03/22/2005US6869945 Antihistamines; respiratory system disorders; antiinflammatory agents
03/22/2005US6869943 Sorbitol dehydrogenase inhibitors
03/22/2005US6869625 Administering an effective amount of an Argyrolobium roseum extract containing flavonoid glycoside compound for therapy of hyperglycemia non-insulin dependent diabetes mellitus in an animal
03/22/2005US6869621 Diet composition comprising raw foods and dietary fibers
03/22/2005CA2330092C Benzimidazole compounds as orl1-receptor agonists
03/17/2005WO2005024063A1 Method of diagnosis of obesity
03/17/2005WO2005023803A1 Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
03/17/2005WO2005023798A1 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
03/17/2005WO2005023790A1 (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid sodium salt
03/17/2005WO2005023789A1 Phosphoric acid salt of (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid
03/17/2005WO2005023782A1 Substituted fused pyrimidine-4(3h)-one compound
03/17/2005WO2005023779A1 Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt
03/17/2005WO2005023777A1 Ppar-activating compound and pharmaceutical composition containing same
03/17/2005WO2005023771A1 Chemokine receptor antagonist and medical use thereof
03/17/2005WO2005023766A1 Salt of atorvastatin with metformin
03/17/2005WO2005023764A1 Salt of atorvastatin with ranitidine
03/17/2005WO2005023762A1 Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
03/17/2005WO2005023291A2 Use of glp1-agonists in the treatment of patients with type i diabetes
03/17/2005WO2005023253A1 Use of pde4 inhibitors for the treatment of diabetes mellitus
03/17/2005WO2005023238A1 Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
03/17/2005WO2005023234A1 Molecules exhibiting anti-adipogenic activity on adipocyte human cells
03/17/2005WO2005023231A1 Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
03/17/2005WO2005000820A3 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists
03/17/2005WO2004111008A3 Use of a compound of formula i for making a pharmaceutical composition
03/17/2005WO2004096266A8 Improved physical stability of insulin formulations
03/17/2005WO2004071399A3 Modulation of atp production or content in the hypothalamus
03/17/2005WO2004054601A3 Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
03/17/2005WO2003092614A3 Lipid removal from the body
03/17/2005WO2003045918A8 Piperidine-based mch antagonists for treatment of obesity and cns disorders
03/17/2005WO2003037887A8 Therapeutic isoquinoline compounds
03/17/2005WO2002050028A8 Substituted benzoindoles as spla2 inhibitors
03/17/2005US20050059810 Dibenzylamine compound and medicinal use thereof
03/17/2005US20050059729 Substituted cyclic compounds
03/17/2005US20050059726 For treating thrombosis and factor xa-related cardiovascular and neurodegenerative diseases; 6-Chloro-N-{(3S)-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide for example
03/17/2005US20050059714 2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol; treating diseases of inflammatory, allergic, or proliferative condition; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumor
03/17/2005US20050059711 Potentiators of insulin secretion
03/17/2005US20050059700 Reacting compunds such as 6-methyl-12-oxa-tricyclo[8.2.1.0]trideca-2,4,6-trien-11-ol with compounds such as 4-(2,6-dichloro-phenyl)-piperidine to produce (+-)-cis-1-methyl-7-[[4-(2,6-dichloro-phenyl)piperidin-1-yl)]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol
03/17/2005US20050059686 Pyrrolopyrimidines as phosphodiesterase vII inhibitors
03/17/2005US20050059683 A1 adenosine receptor antagonists
03/17/2005US20050059662 Substituted quinazolinone compounds
03/17/2005US20050059652 Open chain prolyl urea-related modulators of androgen receptor function
03/17/2005US20050059650 1H-pyrazolo[3,4-d]pyrimidine derivatives as antidiabetic and antiobesity agent
03/17/2005US20050059618 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
03/17/2005US20050059614 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
03/17/2005US20050059601 by administering an exendin peptide analog of given amino acid sequence; treating Type II diabetes, eating disorders, and insulin-resistance syndrome
03/17/2005US20050059600 Chimeric natriuretic peptides
03/17/2005US20050059577 Glycosylphosphatidylinositol containing polypeptides
03/17/2005US20050059144 MHC class II antigen-presenting systems and methods for activating CD4+ T cells
03/17/2005US20050059108 Expression vector comprising nucleotide sequences coding neurotransmitter for use in prevention and treatment of obesity, anorexia, energy imbalance, diabetes, dyslipidemia, hypertension and/or insulin resistance
03/17/2005US20050059093 Method for detecting modulators of Notch signalling
03/17/2005US20050059081 Dipeptidyl peptidase IV (DPPIV); homology with family of prolyl oligopeptidases; drug screening for enzyme inhibitors for DPPIV which could treat reproductive, inflammatory and metabolic disorders; antibodies for therapeutic or diagnostic use; host cells
03/17/2005DE10306502B4 Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel Substituted 3- (Benzoylureido) -thiophenderivate and medicaments containing them
03/17/2005CA2537230A1 Use of pde4 inhibitors for the treatment of diabetes mellitus
03/16/2005EP1514942A1 Method of searching substane having antidiabetic activity
03/16/2005EP1514869A1 Indole, indazole, and benzazole derivative
03/16/2005EP1514559A1 Arylpiperazines having activity at the serotonin 1a receptor
03/16/2005EP1514552A1 Novel fused imidazole derivative
03/16/2005EP1514550A2 Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
03/16/2005EP1514547A1 Controlled-release drug composition
03/16/2005EP1513942A2 Galactosyl isomalt, method for production and use thereof
03/16/2005EP1513880A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
03/16/2005EP1513875A2 Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
03/16/2005EP1513864A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/16/2005EP1513862A2 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
03/16/2005EP1513858A2 Process for the preparation of heterocyclyl substituted adenosine derivatives
03/16/2005EP1513842A1 Substituted hexahydropyrrolo (1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines
03/16/2005EP1513840A2 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
03/16/2005EP1513839A1 3-substituted quinuclidines and their use
03/16/2005EP1513837A1 Thiazole derivatives as phosphodiesterase iv inhibitors
1 ... 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 ... 1298